Junshi Biosciences' Cancer Drug Gets Approval for 2 Indications from European Commission

MT Newswires Live

2024/09/25

The European Commission has approved Shanghai Junshi Biosciences' (HKG:1877) toripalimab for the treatment of two indications, a Tuesday bourse filing said.

The first indication comprises toripalimab in combination with cisplatin and gemcitabine to treat adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma.

The second indication involves toripalimab in combination with cisplatin and paclitaxel for the treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.

Shares of the company were up over 3% on Wednesday's close.

Price (HKD): $11.50, Change: $+0.36, Percent Change: +3.23%

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2470328053"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2470328053\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2470328053?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-25 16:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2470328053","market":"sh","top_or_hot":-1,"title":"Junshi Biosciences' Cancer Drug Gets Approval for 2 Indications from European Commission","media":"MT Newswires Live","content":"<html><body><p> The European Commission has approved Shanghai Junshi Biosciences' (HKG:1877) toripalimab for the treatment of two indications, a Tuesday bourse filing said.</p><p>The first indication comprises toripalimab in combination with cisplatin and gemcitabine to treat adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma.</p><p>The second indication involves toripalimab in combination with cisplatin and paclitaxel for the treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.</p><p>Shares of the company were up over 3% on Wednesday's close.</p><p>Price (HKD): $11.50, Change: $+0.36, Percent Change: +3.23%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Junshi Biosciences' Cancer Drug Gets Approval for 2 Indications from European Commission</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJunshi Biosciences' Cancer Drug Gets Approval for 2 Indications from European Commission\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-09-25 16:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> The European Commission has approved Shanghai Junshi Biosciences' (HKG:1877) toripalimab for the treatment of two indications, a Tuesday bourse filing said.</p><p>The first indication comprises toripalimab in combination with cisplatin and gemcitabine to treat adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma.</p><p>The second indication involves toripalimab in combination with cisplatin and paclitaxel for the treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.</p><p>Shares of the company were up over 3% on Wednesday's close.</p><p>Price (HKD): $11.50, Change: $+0.36, Percent Change: +3.23%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2470328053","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2470328053","pubTimestamp":1727253203,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"The European Commission has approved Shanghai Junshi Biosciences'  toripalimab for the treatment of two indications, a Tuesday bourse filing said.The first indication comprises toripalimab in combination with cisplatin and gemcitabine to treat adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma.The second indication involves toripalimab in combination with cisplatin and paclitaxel for the treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.Shares of the company were up over 3% on Wednesday's close.Price : $11.50, Change: $+0.36, Percent Change: +3.23%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4526":"热门中概股","BK1515":"抗疫概念","HKD":"尚乘数科","BK1161":"生物科技","BK4585":"ETF&股票定投概念","BK4023":"应用软件","BK1583":"高瓴概念","01877":"君实生物"},"translate_title":"君实生物抗癌药获欧盟委员会2项适应症批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01877":0.9,"HKD":1},"content_text":"The European Commission has approved Shanghai Junshi Biosciences' (HKG:1877) toripalimab for the treatment of two indications, a Tuesday bourse filing said.The first indication comprises toripalimab in combination with cisplatin and gemcitabine to treat adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma.The second indication involves toripalimab in combination with cisplatin and paclitaxel for the treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.Shares of the company were up over 3% on Wednesday's close.Price (HKD): $11.50, Change: $+0.36, Percent Change: +3.23%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}